Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL

Adam S. Kittai, Matthew Lunning, Alexey Danilov

Research output: Contribution to journalReview article

Abstract

Purpose of Review: Clinicians continue to utilize prognostic biomarkers, such as expression of CD38 and ZAP-70, IGHV mutational status, cytogenetic abnormalities, and genomic aberrations in TP53, to guide prognosis and treatment of patients with CLL. These biomarkers have been validated with standard chemoimmunotherapy. Here, we discuss whether these biomarkers maintain their prognostic significance in the era of targeted therapy. Recent Findings: Multiple phase 3 clinical trials have now proven improved efficacy of targeted therapy over traditional chemoimmunotherapy. We now have ample prospective data using targeted therapy to critically evaluate whether prior prognostic biomarkers remain relevant. Summary: High-risk features do not have the same magnitude of effect on clinical outcomes in the era of targeted therapy when compared to chemoimmunotherapy. Aberrations in TP53 continue to predict inferior outcomes. More research is needed to determine what features confer poor prognosis when targeted therapy is used to treat CLL.

Original languageEnglish (US)
JournalCurrent Hematologic Malignancy Reports
DOIs
StatePublished - Jan 1 2019

Fingerprint

Biomarkers
Therapeutics
Phase III Clinical Trials
Chromosome Aberrations
Research

Keywords

  • Biomarkers
  • Chronic lymphocytic leukemia
  • CLL
  • Prognosis
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL. / Kittai, Adam S.; Lunning, Matthew; Danilov, Alexey.

In: Current Hematologic Malignancy Reports, 01.01.2019.

Research output: Contribution to journalReview article

@article{426b2d4fb1014391bc6541c370e8db13,
title = "Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL",
abstract = "Purpose of Review: Clinicians continue to utilize prognostic biomarkers, such as expression of CD38 and ZAP-70, IGHV mutational status, cytogenetic abnormalities, and genomic aberrations in TP53, to guide prognosis and treatment of patients with CLL. These biomarkers have been validated with standard chemoimmunotherapy. Here, we discuss whether these biomarkers maintain their prognostic significance in the era of targeted therapy. Recent Findings: Multiple phase 3 clinical trials have now proven improved efficacy of targeted therapy over traditional chemoimmunotherapy. We now have ample prospective data using targeted therapy to critically evaluate whether prior prognostic biomarkers remain relevant. Summary: High-risk features do not have the same magnitude of effect on clinical outcomes in the era of targeted therapy when compared to chemoimmunotherapy. Aberrations in TP53 continue to predict inferior outcomes. More research is needed to determine what features confer poor prognosis when targeted therapy is used to treat CLL.",
keywords = "Biomarkers, Chronic lymphocytic leukemia, CLL, Prognosis, Targeted therapy",
author = "Kittai, {Adam S.} and Matthew Lunning and Alexey Danilov",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11899-019-00511-1",
language = "English (US)",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL

AU - Kittai, Adam S.

AU - Lunning, Matthew

AU - Danilov, Alexey

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose of Review: Clinicians continue to utilize prognostic biomarkers, such as expression of CD38 and ZAP-70, IGHV mutational status, cytogenetic abnormalities, and genomic aberrations in TP53, to guide prognosis and treatment of patients with CLL. These biomarkers have been validated with standard chemoimmunotherapy. Here, we discuss whether these biomarkers maintain their prognostic significance in the era of targeted therapy. Recent Findings: Multiple phase 3 clinical trials have now proven improved efficacy of targeted therapy over traditional chemoimmunotherapy. We now have ample prospective data using targeted therapy to critically evaluate whether prior prognostic biomarkers remain relevant. Summary: High-risk features do not have the same magnitude of effect on clinical outcomes in the era of targeted therapy when compared to chemoimmunotherapy. Aberrations in TP53 continue to predict inferior outcomes. More research is needed to determine what features confer poor prognosis when targeted therapy is used to treat CLL.

AB - Purpose of Review: Clinicians continue to utilize prognostic biomarkers, such as expression of CD38 and ZAP-70, IGHV mutational status, cytogenetic abnormalities, and genomic aberrations in TP53, to guide prognosis and treatment of patients with CLL. These biomarkers have been validated with standard chemoimmunotherapy. Here, we discuss whether these biomarkers maintain their prognostic significance in the era of targeted therapy. Recent Findings: Multiple phase 3 clinical trials have now proven improved efficacy of targeted therapy over traditional chemoimmunotherapy. We now have ample prospective data using targeted therapy to critically evaluate whether prior prognostic biomarkers remain relevant. Summary: High-risk features do not have the same magnitude of effect on clinical outcomes in the era of targeted therapy when compared to chemoimmunotherapy. Aberrations in TP53 continue to predict inferior outcomes. More research is needed to determine what features confer poor prognosis when targeted therapy is used to treat CLL.

KW - Biomarkers

KW - Chronic lymphocytic leukemia

KW - CLL

KW - Prognosis

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85065448445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065448445&partnerID=8YFLogxK

U2 - 10.1007/s11899-019-00511-1

DO - 10.1007/s11899-019-00511-1

M3 - Review article

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -